Oncorena initiates the clinical phase I-II study with Orellanin in advanced kidney cancer patients at Karolinska University Hospital in Sweden
LUND, Sweden, February 1, 2022 / PRNewswire / – Oncorena today announced the initiation of the Phase I-II clinical trial of the first-class compound orellanine in patients with advanced renal cancer on dialysis. The company is dedicated to developing a unique and potential breakthrough therapy for advanced kidney cancer.
The drug candidate orellanine, which has a unique mode of action, is being developed for organ-specific chemotherapy with curative potential for patients with advanced kidney cancer undergoing dialysis due to renal failure. Preclinical evidence shows that orellanine specifically exerts potent antitumor effects on metastatic renal cancer in various preclinical models.
The Phase I-II clinical trial will include up to 40 patients and may include patients from other European countries. The clinical trial is carried out in collaboration with the Center for Clinical Cancer Studies, Karolinska University Hospital in Stockholm, Sweden. As the patients are dependent on dialysis, hemodialysis takes place in collaboration with a team at the dialysis unit at Karolinska Hospital. The study is coordinated together with a clinical research organization specialist in oncological clinical trials.
“There is a great medical need for improved treatment options in patients with advanced kidney cancer undergoing dialysis. We look forward to the important clinical development phase in this area of therapy. It is our hope that the results of our clinical study will be beneficial for patients in the future. , says Lars Grundemar, CEO of Oncorena.
This edition discusses the investigative use of an evolving agent and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any trial use of such a product will successfully complete the clinical development or obtain the approval of the health authority.
For further information, please contact
Lars Grundemar, MD, Ph.D., CEO, Oncorena AB
E-mail: [email protected]
Phone +46 (0) 76 209 5518
About the clinical phase I-II trial
In 2021, the Medical Products Agency approved Oncorena’s first clinical trial of orellanine in patients with advanced kidney cancer undergoing dialysis. The Phase I-II clinical trial of orellanine records patients with advanced renal cancer who are already undergoing dialysis due to renal failure. The study is conducted at the Center for Clinical Cancer Studies at Karolinska University Hospital in Stockholm, Swedenand will study the safety, tolerability, pharmacokinetics and evidence of antitumor effects during treatment with a synthetic form of orellanine.
About orellanine
Orellanine, which has a new and unique mode of action, is being developed for organ-specific chemotherapy with curative potential for patients with advanced kidney cancer undergoing dialysis. Orellanine is found in fungi Cortinarius family, these are sometimes picked and eaten by mistake because they are confused with funnel chanterelles. The clinical effects of orellanine are well documented and are completely limited to the kidneys. Orellanine is expected to have a positive effect on the two most common forms of kidney cancer: clear cell and papillary kidney cancer. About 90% of kidney cancer patients suffer from these types of cancer.
About kidney cancer
Approximately 400,000 patients suffer from kidney cancer globally, according to the WHO. The disease can often be cured by surgery if it is detected in time, but unfortunately the diagnosis is often made when the tumor has already spread to other organs. The prognosis is then considerably worse and some groups have a median survival of less than two years. Today, the disease is treated with various types of targeted and immunoactive drugs, often with severe side effects, and common chemotherapy drugs have a limited effect. There is therefore a great and urgent medical need for new, effective and safe drugs.
About Oncorena
Oncorena AB is a Swedish pharmaceutical company with headquarters in Grove. The company is developing a new potential breakthrough treatment for patients with advanced kidney cancer. The treatment is based on research at the university in Gothenburg, Sweden, led by professors Börje Haraldsson and Jenny Nyström. The project was initially developed with support from Vinnova, Sweden Innovation Agency, GU Ventures at the University of Gothenburg and private business angels. Today, Oncorena is mainly financed by the investment companies HealthCap, Linc AB, Fåhraeus Startup and Growth AB and the biotechnology company AQILION AB. For more information, visit Oncorena’s website www.oncorena.com
This information was sent to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Oncorena AB